CHEK1 and neoplasm: Moreover, most of the SL-based targets observed in the literature are pharmacologically induced (e.g.via CHEK1 inhibition), but alterations to these targets are not naturally occurring in tumours (CHEK1 is not frequently lost in tumours), and this explains why some of these genes highlighted in the literature do not turn up in our list.